SGRL629.00

Shree Ganesh Remedies Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSHUKRAPHARSUNLOC
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Returns
Return on Common Equity23.0315.9110.90
Return on Assets16.4512.038.56
Return on Capital Employed16.8613.19
Return on Invested Capital19.0614.0910.82
Margins
EBITDA Margin33.2136.1132.04
Operating Margin28.3627.3022.46
Incremental Operating Margin35.00-739.66
Pretax Margin30.3228.8221.97
Net Income Margin22.3321.2716.26
FCF Margin28.2421.73
Additional
Effective Tax Rate26.3426.2025.99
Sustainable Growth Rate23.0315.9110.90
Incremental Operating Margin %35.00-739.66
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.